STEALTHYX THERAPEUTICS AND CANCER RESEARCH TECHNOLOGY ANNOUNCE CO-DEVELOPMENT PARTNERSHIP FOR TUMOUR-TARGETED THERAPY

Cancer Research Technology (CRT), the specialist oncology development and commercialisation company, and Stealthyx Therapeutics, the disease targeting drug company spin out of Queen Mary, University of London have entered into an agreement to co-develop Stealthyx's proprietary drug delivery platform, Prothyx. The Prothyx platform adds extra functionality to therapeutic molecules making them preferentially active at sites of disease.
News-medical.net